Yahoo Finance • 15 days ago
* KalVista Pharmaceuticals (NASDAQ:KALV [https://seekingalpha.com/symbol/KALV]) announced [https://seekingalpha.com/pr/20243780-kalvista-prices-upsized-offering-of-125_0-million-of-3_250-percent-convertible-senior-notes] on Wednesday the... Full story
Yahoo Finance • 15 days ago
* KalVista Pharmaceuticals (NASDAQ:KALV [https://seekingalpha.com/symbol/KALV]) plans to offer $110M in convertible senior notes due 2031 via private placement. * An additional $15M in notes may be issued if initial purchasers exercise... Full story
Yahoo Finance • 28 days ago
The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is up +0.66%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futures/q... Full story
Yahoo Finance • 28 days ago
The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is up +0.22%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futures/q... Full story
Yahoo Finance • 28 days ago
KalVista Pharmaceuticals Inc (NASDAQ:KALV [https://www.chartmill.com/stock/quote/KALV/profile]) reported its fiscal first-quarter 2026 financial results, delivering revenue that fell short of analyst expectations while posting a wider-than... Full story
Yahoo Finance • 28 days ago
* KalVista Pharmaceuticals press release [https://seekingalpha.com/pr/20229221-kalvista-pharmaceuticals-provides-operational-update-and-reports-fiscal-quarter-financial] (NASDAQ:KALV [https://seekingalpha.com/symbol/KALV]): Q1 GAAP EPS o... Full story
Yahoo Finance • 28 days ago
September S&P 500 E-Mini futures (ESU25 [https://www.barchart.com/futures/quotes/ESU25]) are up +0.16%, and September Nasdaq 100 E-Mini futures (NQU25 [https://www.barchart.com/futures/quotes/NQU25/overview]) are up +0.15% this morning as... Full story
Yahoo Finance • 29 days ago
The S&P 500 Index ($SPX) (SPY) on Wednesday closed up +0.30%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.48%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.04%. September E-mini S&P futures (ESU25) rose +0.28%, and... Full story
Yahoo Finance • last month
The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is down -0.56%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futures... Full story
Yahoo Finance • last month
The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is down -0.11%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futures... Full story
Yahoo Finance • last month
The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is up +0.83%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futures/q... Full story
Yahoo Finance • last month
The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) on Thursday rose +0.84%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futu... Full story
Yahoo Finance • last month
On Wednesday, KalVista Pharmaceuticals stock reached an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 82, up from 79 the day before. Is KalVista Pharmaceutic... Full story
Yahoo Finance • 3 months ago
Investing.com - JMP Securities has reiterated its Market Outperform rating and $27.00 price target on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), currently trading at $15.17, following UK approval of the company’s HAE treatment. The target... Full story
Yahoo Finance • 3 months ago
[Blue Capsules on Conveyor at Modern Pharmaceutical Factory. Tablet and Capsule Manufacturing Process. Close-up Shot of Medical Drug Production Line.] SweetBunFactory/iStock via Getty Images * KalVista Pharmaceuticals (NASDAQ:KALV [http... Full story
Yahoo Finance • 3 months ago
Investing.com - H.C. Wainwright has reiterated a Buy rating and $27.00 price target on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), representing a 74% upside from the current price of $15.51, following the FDA approval of its hereditary ang... Full story
Yahoo Finance • 3 months ago
Benjamin L. Palleiko, Chief Executive Officer of KalVista Pharmaceuticals (NASDAQ:KALV), sold 32,979 shares of common stock on July 9, 2025, at a price of $15.6925, for a total transaction value of $517,522. The sale comes as the stock tra... Full story
Yahoo Finance • 3 months ago
Yea Christopher, Chief Development Officer of KalVista Pharmaceuticals Inc (NASDAQ:KALV), sold 30,250 shares of common stock on July 9, 2025, at a price of $15.6925, totaling $474,698. The sale comes as the stock trades near its 52-week hi... Full story
Yahoo Finance • 3 months ago
Investing.com - Leerink Partners has reiterated an Outperform rating and $20.00 price target on Kalvista Pharmaceuticals Inc (NASDAQ:KALV) following the company’s fiscal fourth-quarter 2025 financial results and corporate update. The stock... Full story
Yahoo Finance • 3 months ago
BofA raised the firm’s price target on KalVista (KALV) to $37 from $22 and keeps a Buy rating on the shares after the company announced the approval of Ekterly for on-demand treatment of hereditary angioedema attacks with a broad label and... Full story